Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer TherapyFirdous H Beigh1, Nidda Syeed2, Mohsin Maqbool3 and Rita Singh Majumdhar1*
- Corresponding Author:
- Prof. Rita Sing Mujamdhar
Prof & Head Department of Biotechnology
Sharda University, India
Tel: 0120 457 0000
E-mail: [email protected]
Received Date: May 01, 2017; Accepted Date: May 11, 2017; Published Date: May 17, 2017
Citation: Beigh FH, Syeed N, Maqbool M, Majumdhar RS (2017) Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy. J Stem Cell Res Ther 7:388. doi: 10.4172/2157-7633.1000388
Copyright: © 2017 Beigh FH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prostate cancer (CaP) is considered as a vexing challenge for clinical management because of its resistance to the conventional therapies, resulting in most deaths from this disease. The current treatment options including castration shows minimal effect, as most of the patients develop resistance and relapse of more aggressive Castration Resistant Prostate Cancer (CRPC). BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), an oncogenic member of the polycomb group gene family and a transcriptional repressor has emerged as a key regulator in numerous processes including proliferation, differentiation, senescence, and stem cell renewal. Accumulating evidences have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in most human malignancies, including Prostate cancer. Therefore, in this review, we provide the significant evidences suggesting the potential of BMI1 as a therapeutic target in the management of prostate cancer.